TickerKhojComparison · NSE · data 2026-11-02
Bliss GVS Pharma Limited vs Sanofi India Limited
In plain words
Size: Sanofi India Limited is about 1.1 times the market value of Bliss GVS Pharma Limited.
Valuation (P/E): Bliss GVS Pharma Limited 49.6 vs Sanofi India Limited 20.8.
Return on equity: Sanofi India Limited 40.6% vs Bliss GVS Pharma Limited 11.5%.
Profit growth over 3 years: Bliss GVS Pharma Limited 22.1% a year vs Sanofi India Limited -19.3% a year.
Differences in the numbers, not a recommendation of either stock.
Side by side
| BLISSGVS | SANOFI | |
|---|---|---|
| Price | ₹626 | ₹3,289.3 |
| Market cap | ₹6,894 cr | ₹7,380 cr |
| P/E | 49.6 | 20.8 |
| P/B | — | — |
| ROE | 11.5% | 40.6% |
| ROCE | 10.9% | 54.6% |
| Debt / equity | 0.02 | 0.02 |
| Operating margin | 15.1% | 26.3% |
| Dividend yield | 0.23% | 3.84% |
| Sales growth, 3 years (yearly) | 7.2% | -12.8% |
| Profit growth, 3 years (yearly) | 22.1% | -19.3% |
| 1-year return | 300.8% | -31.5% |
| Revenue, last 12 months | ₹1,005 cr | ₹1,822 cr |
| Net profit, last 12 months | ₹136 cr | ₹365 cr |
| Latest quarter | Sept 2026 | Sept 2026 |
| Quarter net profit | ₹52 cr | ₹117 cr |
| Quarter profit vs a year earlier | +91.7% | +53.6% |
| Promoter holding | 50.07% | 60.40% |
| Health check | Strong (6.6/10) | Average (6.3/10) |
Common questions
Which has a higher P/E, Bliss GVS Pharma Limited or Sanofi India Limited?
Bliss GVS Pharma Limited trades at the higher P/E (49.6 against 20.8). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Sanofi India Limited (40.6% against 11.5%).
Which carries more debt?
Bliss GVS Pharma Limited has the higher debt-to-equity ratio (0.02 against 0.02).